Source: Trial Site News Author: Mary Beth Pfeiffer

A Yale University professor and renowned cancer researcher has pored over the COVID-19 literature and treated several dozen patients. He can remain silent no longer.

Dr. Alessandro Santin, a practicing oncologist and scientist who runs a large laboratory at Yale, believes firmly that ivermectin could vastly cut suffering from COVID-19. Santin joins a growing group of doctors committed to using the safe, generic drug both as an early home treatment to prevent hospitalization and alongside inpatient treatments like steroids and oxygen.

“The bottom line is that ivermectin works. I’ve seen that in my patients as well as treating my own family in Italy,” Santin said in an interview, referring to his father, 88, who recently suffered a serious bout of COVID. “We must find a way to administer it on a large scale to a lot of people.”

Santin’s statements carry the prestige of a leadership position at Yale School of Medicine and the gravitas of a top uterine cancer researcherwho has authored more than 250 science journal articles and pioneered treatment, used worldwide, for the most aggressive form of uterine cancer. At Yale, he is an OB/GYN professor, team leader in gynecologic oncology at the Smilow Comprehensive Cancer Center, and co-chief of gynecologic oncology.

Improvement Across the Board

When COVID came along, Santin began reading about how best he might help his cancer patients, 10 to 20 percent of whom were coming in infected with COVID. He began using ivermectin after the National Institutes of Health changed its advisory in January to allow the drug’s use outside of COVID trials.

Santin’s endorsement is not only important but broad. He said he has seen ivermectin work at every stage of COVID — preventing it, eliminating early infection, quelling the destructive cytokine storm in late infection, and helping about a dozen patients so far who suffered months after COVID. One of them is an athlete and mother of two, 39, who had been disabled by post-COVID chest pain, shortness of breath and fatigue; she confirmed in an email to me her joy at being able to walk up a hill again and breathing better within 72 hours of her first dose.

“When you have people that can’t breathe for five, six, eight, nine months and they tried multiple drugs and supplements with no success, and you give them ivermectin,” Dr. Santin said of long-haul patients, “and you see that they start immediately feeling better, this is not placebo. This is real.” 

The majority of patients improved within one to three days, he said, particularly those with breathing problems, debilitating fatigue and chest pain. Two draft studies from Peru have reported improvement with ivermectin in long-haul patients; several physicians, like Santin, have also had anecdotal success.

Beyond his outpatients, Santin has treated family members and friends infected with COVID in both his home community in Connecticut and in his native Italy via telemedicine. There, he prescribed ivermectin to more than 15 families, in which parents, children or others had became infected; the goal was both to treat early and prevent severe COVID, as studies have shown ivermectin does.

“I have not a single one that right now had to go to the hospital to receive oxygen,” he said. “I have no doubt ivermectin saved my 88-year-old father’s life.” His father survived COVID despite high blood pressure, cardiac disease that led previously to seven stents and open heart surgery, and lung problems. “If I can save you,” he said referring to his father, “I can tell you, I save anybody.”

Santin said he has also consulted on inpatient care with a colleague at a hospital in his native Brescia, one of the cities hardest hit by COVID in Italy.

Two Italian newspapers first reported Dr. Santin’s experience with ivermectin, on March 5 and March 18. In the first article, he told the newspaper il Fatto Quotidiano, “Ivermectin can really be the game-changer against COVID-19.” He reported seeing cancer patients “radically improve their shortness of breath and oxygenation” within 24 to 48 hours of their first dose.

In a subsequent article in Affaritaliani newspaper, he described his surprise after first reading the body of 40 positive ivermectin studies and then using the drug on patients. “I did not expect that a drug approved over 35 years ago with other indications [namely to treat parasitic worms and scabies] could really be so effective and well tolerated in COVID patients,” he said.

In both articles and in my interview, Santin pointed to the crucial advocacy of Dr. Pierre Kory, an ICU specialist and perhaps the nation’s strongest voice for ivermectin as president of Frontline COVID-19 Critical Care Alliance.

Doctors: Read the Research

Kory said Santin’s experience is typical of doctors who take time to scour the new ivermectin research. “I’m just so encouraged that other thoughtful clinicians are able to assess, to investigate, to look at the evidence and make a judgment on the risk-benefit analysis,” he said of Santin.

Both physicians faulted doctors who don’t read emerging science and instead follow rigid hospital protocols; these notably leave out ivermectin, even though the drug has now been given the same neutral NIH recommendation as monoclonal antibodies and convalescent plasma.

As a result, newly diagnosed COVID patients are typically told, as they have been for a year: Go home, take acetaminophen perhaps, and go to the hospital when breathing gets tough. In other words, get sicker before you get care.

But even hospital care has huge gaps. “When you are an inpatient with severe COVID right now, “ Santin said, “you give them a steroid, you give them heparin and remdesivir. That’s it. If they improve, great. If they get worse, you unfortunately keep on watching them die.”

“I was very disappointed, and I’m still very disappointed, about the treatment protocols that we currently are providing to patients,” he said. This is why, he told me, he has decided to speak out.

Kory and Santin differ in one respect. Kory believes long-haul syndrome is driven largely by inflammation; Santin sees a significant role for persistent infection, namely live lingering viruses.

In the scheme of things, this is a small issue. The key to halting COVID is to use the drug, both doctors agree. Instead, mainstream medicine, the press and public health officials in the U.S. and Europe ignore it, while India, Bangladesh, Peru, the Czech Republic, and other countries reap its benefits.

Put Focus On Therapies

The Western approach to long-haul COVID is a case in point. Studies at many university centers are focused in general not on treatment therapies but on defining the long-haul syndrome. As a result, Kory said, patients with cognitive issues, pain, breathing and heart problems are referred to specialists with few tools to help them.  This may be understandable given that long-haul research is scant and raw.

But for doctors like Santin and Kory, existing safety data and clinical research gives ample reason to try ivermectin at every stage, including in the 10 percent who have what the FLCCC calls “persistent, vexing, and even disabling symptoms after recovery.” 


Fred Wagshul, a pulmonologist in Dayton, Ohio, tried ivermectin for five to seven days in what he called “true long-haulers.” Most reported significant improvement in days. Similarly, Peruvian researcher, Gustavo Aguirre-Chang, reported on 33 long-haul patients who were given ivermectin one to three months after resolution; 88 percent got better with two daily doses.

The Story of Sam Dann

Sam Dann is the poster boy for what COVID can do to a muscular, active 41-year-old and regular jogger. Like many other patients, he was sent home after a positive test last July with the advice to “drink Gatorade and take Tylenol.” 

Over the next months, “I went through an absolute living hell,” he told me, that was worse than three tours in Iraq.

After the initial bout of infection, he experienced crippling fatigue, anxiety, sleeplessness and nightmares, uncontrollable tremors, a racing heartbeat, and an inability to think straight or recall basic information. He could not work.

Some six months into his grueling odyssey, Dann went to Dr. Bruce Boros, a Key West, Florida, cardiologist and urgent care center owner who, after treating about 200 patients with ivermectin, is now offering it prophylactically. There, Dann got a 10-day prescription for ivermectin.

The vertigo went away almost immediately. The tremors calmed. The nights were difficult but gradually improved. The pain went from 8, on a scale of 10, to 1 to 3. “I still get weird feelings here and there,” he told me, “but I’m nowhere where I used to be.”

Despite stories like this, every day in the United States and elsewhere, we are minting new long-haul patients just like Sam Dann. Said Dann, “There are a lot of dead people because they refused to acknowledge this drug’s usage.”

Santin’s advice to doctors who unquestioningly follow COVID protocols is this:

“Use your brain. If your patient is dying, change something, try to do something more.”

Of ivermectin, he said, “It’s safe, it’s cheap and it works.”









Related: Ivermectin is effective for COVID-19: real-time meta analysis of 42 studies

Portugal: from hydroxychloroquine to ivermectin

The lawyer who won the Ivermectin battle for South Africans

How a father & his daughter survived COVID-19: Ivermectin

The home care protocol for Covid has been updated to include hydroxychloroquine: Piedmont, Italy

UK: Lice and scabies drug, Ivermectin, could cut Covid deaths by up to 75%, research suggests

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »

The Chloroquine Wars Part XIV – How to Rig Research: Surgisphere Part I

It was in these very moments in late May when public health officials lost all credibility—a credibility that cannot be restored without major changes taking place. Despite most evidence pointing to a likelihood of HCQ efficacy, they made their call on the back of data supposedly tucked away in a database that nobody had verified, declared it definitive, then swiftly pushed for policy changes around the world.

Read More »